BioDuro has appointed Andrew Thomas (top left) and Stevan Djuric (top right) as Scientific Advisors.
Thomas was formerly Global Head of Medicinal Chemistry, Small Molecule Research at Roche, where he was a member of the Therapeutics Modalities Leadership Team and led global teams responsible for advancing innovative drug discovery programmes across multiple therapeutic areas. More recently, he has managed two investment funds focused on Swiss technology growth companies.
In his new role, Thomas will provide strategic guidance to both clients and the company’s scientific and operational teams, helping to strengthen the company’s capabilities in innovative drug discovery and development.
Thomas is focused on transforming impactful innovation in the healthcare sector and has published more than 100 patents, peer-reviewed journals and books, with his most notable Roche success being his team’s invention and development of Evrysdi to treat spinal muscular atrophy.
Djuric is President of Discovery Chemistry and Technology Consulting. In his new role, Djuric will provide strategic guidance to both clients and the company’s scientific and operational teams, helping to strengthen the company’s capabilities in innovative drug discovery and development.
Previously, he served as Vice President of Discovery Chemistry and Technology at AbbVie, where he led both the company’s medicinal and discovery chemistry teams. With more than three decades of experience in pharmaceutical research, he has played a key role in advancing numerous drug discovery programmes and has been widely recognized for his contributions to medicinal chemistry and innovation in drug discovery. During his career at Abbott and AbbVie, he advanced multiple drug discovery programmes into clinical development and contributed to the development of Zotarolimus and other therapeutic innovations.
Armin Spura, CEO of BioDuro, said: “The appointment of Andrew Thomas and Stevan Djuric deepens our commitment to scientific excellence and innovation as we continue to expand our capabilities and support our partners in advancing complex drug discovery programmes.”